Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Other Non-Current Assets (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Other Non-Current Assets for 4 consecutive years, with $322000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Other Non-Current Assets rose 3.87% to $322000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $322000.0, a 3.87% increase, with the full-year FY2023 number at $313000.0, up 3.64% from a year prior.
  • Other Non-Current Assets was $322000.0 for Q3 2024 at Actinium Pharmaceuticals, up from $318000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $392000.0 in Q1 2021 to a low of $50000.0 in Q2 2021.
  • A 4-year average of $251733.3 and a median of $307000.0 in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: tumbled 87.24% in 2022, then skyrocketed 514.0% in 2023.
  • Actinium Pharmaceuticals' Other Non-Current Assets stood at $50000.0 in 2021, then surged by 504.0% to $302000.0 in 2022, then grew by 3.64% to $313000.0 in 2023, then grew by 2.88% to $322000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Other Non-Current Assets are $322000.0 (Q3 2024), $318000.0 (Q2 2024), and $316000.0 (Q1 2024).